OPCH

Option Care Health, Inc.

Fundamental data last updated:September 25, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Medical - Care Facilities

Exchange

NASDAQ

County of HQ

US

Next Earnings Date

Pending Announcement

Business Summary

Option Care Health, Inc. offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including Crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders. It also offers treatments to manage the progression of neurological disorders, such as amyotrophic lateral sclerosis and duchenne muscular dystrophy; infusion therapies for bleeding disorders; therapies that women need to survive and thrive through high-risk pregnancies; and other infusion therapies to treat various conditions, including pain management, chemotherapy, and respiratory medications, as well as nursing services. Option Care Health, Inc. is headquartered in Bannockburn, Illinois.

 


Analyze OPCH on TradingView

VALUATION

P/E

16.40

Market Cap ($M USD)

$3.39B

Forward P/E

7.82

PEG

0.07

PRICE TO SALES

0.60

PRICE TO BOOK

2.50

EV / EBITDA

7.91

5-Year Average P/E

Free Cash Flow Yield

6.95%

DCF Value

$80.90

Graham Number

$15.98

Price to FCF

14.39

EV to FCF

13.64

Earnings Yield

6.10%

FCF Yield

6.95%

DIVIDEND

Yield

0.00%

Annual Payout

$0.00

Payout Ratio

0.00%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

$1.32

Next Year EPS Growth Estimate

$2.76

Next Year Revenue Growth Estimate

$7.70B

Return on Equity (ROE)

15.28%

FREE CASH FLOW

Operating Margin

5.93%

Debt-to-Equity

0.00

Piotroski F-Score

8

Altman Z-Score

3.16

Return on Invested Capital (ROIC)

12.67%

Current Ratio

1.64

Quick Ratio

1.07

Net Debt to EBITDA

-0.44

Interest Coverage

5.50

Gross Profit margin

18.00%

FCF PER SHARE

$1.50

REVENUE PER SHARE

$36.18

Analyze OPCH on TradingView

Gainseekers Quantitative Analysis

Summary

The market seems to be significantly undervaluing Option Care Health, Inc. relative to its intrinsic worth. With a DCF value towering over its recent trading price, the stock appears deeply discounted. The Forward P/E of 7.43 and a PEG ratio of 0.067 suggest robust growth potential at a bargain price. Meanwhile, an Altman Z-score of 3.13 indicates financial stability, reducing bankruptcy risk. This combination of undervaluation and safety makes it a compelling opportunity for value investors.

AI Exposure / Tech Reliance

Operating within the healthcare sector, Option Care Health is well-positioned to leverage AI and technological advancements. As a player in medical care facilities, integrating AI could streamline operations and enhance patient care. This adaptability is crucial in maintaining a competitive edge in a rapidly evolving industry.

The Bull Case

For the discerning GARP investor, Option Care Health offers a tantalizing prospect. A strong ROIC of 12.67% and a Piotroski F-Score of 8 highlight its operational efficiency and financial health. The company’s FCF yield of 7.31% underscores its ability to generate cash, while a gross profit margin of 18% suggests solid pricing power. These metrics paint a picture of a company that not only manages its capital effectively but also has the potential to reward shareholders handsomely.

The Bear Case

Despite its strengths, Option Care Health is not without flaws. The Price/Book ratio of 2.38 and Price/Sales of 0.57 indicate a premium valuation that may not be justified by its current earnings. Additionally, with the stock trading significantly below its 50-Day and 200-Day SMAs, it suggests potential technical weakness. Investors should be cautious of these valuation pressures, which could limit upside potential.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Buy

Average Analyst Price Target

$32.38

Institutional Ownership %

1-Year Beta

0.68

Insider Buying % (6 Mo)

Distance to 52-Week High

70.53%

Distance to 52-Week Low

16.54%

EARNINGS SURPRISE %

8.11%

50-DAY SMA

$25.17

200-DAY SMA

$29.13

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.